PMS has a larger market size than Rett Syndrome (DAYBUE), NEU is the only company that is going to enter PMS phase 3 trial mid 2025, the most advanced development in PMS in the world.
Currently NEU market cap is US$1B with net cash around US$200m including upcoming US$50m milestone payment (to receive this quarter), so NEU's enterprise value is merely US$800m. Given Biogen paid US$7.3B for SKYCLARYS (which is similar market size as Rett Syndrome, DAYBUE). I think Biogen should consider NEU as its valuation is very attractive, imo.
PMS has a larger market size than Rett Syndrome (DAYBUE), NEU is...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.71 |
Change
1.170(9.33%) |
Mkt cap ! $1.730B | |||
| Open | High | Low | Value | Volume |
| $12.96 | $14.00 | $12.91 | $9.460M | 691.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 360 | $13.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.72 | 55 | 2 |
View Market Depth
| Last trade - 12.35pm 26/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |